Sarepta Therapeutics, Inc. Stock 12‑Month Price Target Cut to $22, Implies 14% Upside
Explore more price target data and ratings for Sarepta Therapeutics, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Sarepta Therapeutics, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems In…